ReviewQuantitative imaging in medicine and surgery2015
Current role of multiparametric magnetic resonance imaging for prostate cancer.
Review in Quantitative imaging in medicine and surgery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 32 citations in OpenAlex.
- Preoperative Molecular Subtype Classification Prediction of Ovarian Cancer Based on Multi-Parametric Magnetic Resonance Imaging Multi-Sequence Feature Fusion Network.Bioengineering (Basel, Switzerland) · 2024Article
- Retraction: current role of multiparametric magnetic resonance imaging for prostate cancer.Quantitative imaging in medicine and surgery · 2024Article
- Role of magnetic resonance imaging for preoperative prediction of early biochemical failure in localized prostate cancer.Quantitative imaging in medicine and surgery · 2023Article
- Three-dimensional nuclear magnetic resonance spectroscopy: a complementary tool to multiparametric magnetic resonance imaging in the identification of aggressive prostate cancer at 3.0T.Quantitative imaging in medicine and surgery · 2021Article
- Assessment of prostate imaging reporting and data system version 2.1 false-positive category 4 and 5 lesions in clinically significant prostate cancer.Abdominal radiology (New York) · 2021Article
- Locally advanced prostate cancer imaging findings and implications for treatment from the surgical perspective.Abdominal radiology (New York) · 2020Review
- Multiparametric magnetic resonance imaging: Overview of the technique, clinical applications in prostate biopsy and future directions.Turkish journal of urology · 2018Review
- Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy.British journal of cancer · 2017Article
- Optimal MRI sequences forEJNMMI research · 2017Article
- Magnetic resonance imaging for prostate cancer before radical and salvage radiotherapy: What radiation oncologists need to know.World journal of clinical oncology · 2017Review
- A systematic review on multiparametric MR imaging in prostate cancer detection.Infectious agents and cancer · 2017Review
- Multiparametric [11C]Acetate positron emission tomography-magnetic resonance imaging in the assessment and staging of prostate cancer.PloS one · 2017Article
- Magnetic resonance-ultrasound fusion prostate biopsy in the diagnosis of prostate cancer.Urologic oncology · 2016Review
- Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions.Oncotarget · 2016Review
Corrections and comments
- Retraction · 2024-03-15Euphemisms for Plagiarism · Plagiarism of/in Article ·
- Retracted
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiparametric magnetic resonance imaging (mp-MRI) has shown promising results in diagnosis, localization, risk stratification and staging of clinically significant prostate cancer, and targeting or guiding prostate biopsy. mp-MRI consists of T2-weighted imaging (T2WI) combined with several functional sequences including diffusion-weighted imaging (DWI), perfusion or dynamic contrast-enhanced imaging (DCEI) and spectroscopic imaging. Recently, mp-MRI has been used to assess prostate cancer aggressiveness and to identify anteriorly located tumors before and during active surveillance. Moreover, recent studies have reported that mp-MRI is a reliable imaging modality for detecting local recurrence after radical prostatectomy or external beam radiation therapy. Because assessment on mp-MRI can be subjective, use of the newly developed standardized reporting Prostate Imaging and Reporting Archiving Data System (PI-RADS) scoring system and education of specialist radiologists are essential for accurate interpretation. This review focuses on the current place of mp-MRI in prostate cancer and its evolving role in the management of prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.